It is likely that from December 2012 The University of Manchester I3 Ltd will distribute ‘UMI3 News’ on a bi-annual basis as ane-newsletter. This will feature, as UMIP News has done to-date, the activities of our intellectual property commercialisationdivision but will additionally cover news from our Innovation Centre, UMIC. UMIC and UMIP are divisions of UMI3.

THE UNIVERSITY OF MANCHESTER I3 LTD (UMI3)ROYAL VISIT His Royal Highness The Duke ofYork visited UMI3 in February aspart of a visit to the University tolearn more about graphene andthe University’s successes andchallenges in commercialisingresearch and to meet somestudent technology entrepreneurs.He also visited NanoCo, in theUniversity’s Innovation Centre, asan example of a successfulmanufacturing spin-out whichgrew from a Proof-of-Principleproject to a £100M+ stock-marketlisted company in six years.

Following a tour of the graphenefacilities and a lunch hosted byPresident, Professor Dame NancyRothwell, The Duke of York wasgreeted at the Innovation Centreby Vice-President for Innovation,Professor Luke Georghiou, and

UMI3 CEO, Clive Rowland. His RoyalHighness visited UMI3 as part of hisdesire to see that the UK isrecognised as the best place in theworld for Science and Engineering.

Clive commented: “It was veryencouraging to see howknowledgeable and positivelyengaged The Duke of York isabout research commercialisationand related activities such asstudent enterprise projects. He is keen to see the Universitycontinue to develop its capabilitiesin this regard and promote itssuccesses and productsinternationally. He is extremelyenthusiastic about the potential of graphene and interested in the different applications androutes to market for it.”

ENTREPRENEURSHIP FORUM UPDATE

Successfully launched in January,our Entrepreneurship Forum isgathering momentum with over10 events to-date around OpenInnovation, Angel Networks andthe Manchester MicroMasterclassseries, which covers topics fromsocial media to business pitching.

The Forum’s aim is to connectthe external community, whoseinterests lie in entrepreneurshipand innovation, with theUniversity’s academic/researchcommunity through a series ofworkshops, seminars and events.

Our Open Innovation eventshave attracted speakers fromsome of the biggest corporatenames in industry including;Reckitt Benckiser, ShirePharmaceuticals, GE Healthcare,Pfizer and Lilly. With anunmissable opportunity to hearthe latest ‘most wanted’ areas ofinterest directly from thetechnology sourcing directors,academics and innovators havebeen able to discuss potentialcollaborative opportunities forfuture developments through aseries of 1-2-1 meetings.

For companies seeking investment it is worth notingthat UMI3 continues to host theEnvestors business angelnetwork events within ourInnovation Centre.

For the latest news on upcoming events visit:www.umic.co.uk/events orcontact Ellie Sagarellie.sagar@umi3.com

His Royal Highness The Duke of York with Nanoco’s CEO,Dr Michael Edelman and CTO, Dr Nigel Pickett

A bi-annual update on the activities of UMIP, the University’s agentfor intellectual property management and commercialisation

Issue 7, June 2012

UMIPNEWS

UMIP - REPUTATION AND VALUE THROUGH INTELLECTUAL PROPERTY®

The Core Technology Facility

STOP PRESS: The University of Manchester I3 Limited is pleased to announce that it has just received Investors in People accreditation.

INTELLECTUALPROPERTYRESOURCE

An intranet resource for:

> Understanding IP

> IP Commercialisation

> IP in Research and Consultancy

> IP & Academic Materials

UMIP’s Commercialisation Executives are your first point of callfor any questions you may have should you have an idea orobservation and are wondering if it has potential value.

Our Commercialisation Executives are faculty specific:

MEET YOUR UMIP FRONTLINE CONTACTS

2

If you are working on research that you think has commercialpotential, we would be pleased to hear from you.

ww

w.m

anch

este

r.ac.

uk/i

pres

ourc

e

As previously explained, a significant challengefor a fund such as the UMIP Premier Fund(UPF) when it is four years old is finding co-investors. The UPF is a £32m fund, which issufficiently large to make a significant impact,but not sufficiently large to provide all of thecapital requirements for all of our companiesall of the time. To do this you would need afund closer to £200m. So at some point itbecomes necessary to find co-investors andright now this is the main focus of activity formanaging the UPF.

This is why we are very pleased to closesignificant funding rounds in the last fewquarters with additional investors for many ofour portfolio companies. These includeUniversity spin-outs Ai2 and Arvia Technologyand one of our external investments, PowerOasis. Together these three companies haveraised close to £10m with most of the cashcoming from new professional investors. Giventhe tough economic climate that still exists,raising this money is a significant achievement.

There will be no resting on laurels, however,for two reasons. Firstly this hard earned moneyneeds to be put to work to maximum effect indriving the development of the businesses andsecondly there are other companies in theportfolio that will be raising new funds duringthis year and into next.

Many of our Proof-of-Principle investmentsthat have been supported with UMIP and UPFover the last few years are making goodprogress. These are high risk investments andso a decent failure rate is expected, but asignificant proportion are now being directedtowards either licence deals or towardsbecoming the next University spin-outs. Thesewill also require substantial investment, sowatch this space. The UPF is still open forbusiness for new Proof-of-Principleinvestments and so if you believe yourresearch has commercial potential pleasecontact UMIP.

UMIP PREMIER FUND UPDATE...

Mark RahnInvestment ManagerMTI Partners (Managers of the UMIP Premier Fund)

www.theupf.com

For Technology and Humanities:

Dr Pushkar Wadke, EPST: 0161 306 8832E: pushkar.wadke@umip.com

Dr Mugdha Joshi, EPST: 0161 306 8513E: mugdha.joshi@umip.com

Mr Daniel Syder, HumanitiesT: 0161 306 8512E: daniel.syder@umip.com

For Life Sciences and Medical &Human Sciences:

Dr Arnaud Garçon, FLS/MHST: 0161 603 7757E: arnaud.garcon@umip.com

Dr Edward Maughfling, MHST: 0161 606 7213E: edward.maughfling@umip.com

Dr Gill Shuttleworth, FLST: 0161 603 7738E: gillian.shuttleworth@umip.com

OUR SEED FUND RUNNING SINCE MARCH 2008

MANCHESTER FOOT PAIN AND DISABILITYINDEX (MFPDI) QUESTIONNAIRE

LATEST UMIP LICENSING NEWS

In mid 2010, UMIP assisted ateam from the Faculty of LifeSciences (Simon Merrywest,Louise Barnes, Mark Hagon,Davina Whitnall, LaurenSummers and George Jeffries)with the licensing arrangementsof the ProgressPlatform™software package to otherhigher education institutions.ProgressPlatform™ is an onlinesystem for recording, monitoringand reporting on studentprogression and skills trainingactivity and combines bespoke

progression areas and advancedreporting features to create aninnovative and interactivesystem for tracking studentprogression throughout their studies.

This transparent and easy to usesystem aids compliance with thePoints Based Immigration systemand offers the potential toincrease submission/completionrates. Its range of uses extendsbeyond just postgraduatestudents as undergraduate, CPD,

other taught students andresearch staff can also benefitfrom the system’s flexibility.

ProgressPlatform Director, DrSimon Merrywest commented:“The remarkable thing aboutthis project is that the wholeteam have taken the seed of anidea and followed it through tosuccessful delivery whilst stilldoing their ‘day jobs’. Thesupport of UMIP in navigatingthrough the legal complexitieshas been invaluable. One clienthas even commented that it wasthe smoothest contractnegotiation they had everundertaken.”

The team have nowimplemented the system at theInstitute of Cancer Research, CityUniversity, London and areabout to start work with AngliaRuskin University.

Justin Macklin, Assistant Directorof Academic Services (Systems),Institute of Cancer Researchcommented: “We’ve justlaunched ProgressPlatform atthe Institute of Cancer Research.Initial feedback is incredibly

positive! All users have foundthe system easy to use and weexpect it to make monitoringstudent progression muchsmoother and more efficient.”

www.progressplatform.co.uk

Remember to discuss possible IP protection before you publish. Contact your UMIP Commercialisation Executive first.3

In late 2011, UMIP assisted DrAdam Garrow to assign thecopyright IP of a well-established clinical questionnaire- the Manchester Foot Pain andDisability Index (MFPDI) - to IsisOutcomes, part of IsisInnovation, the University ofOxford’s technology transfercompany. Adam was previously amember of the ArthritisCampaign Epidemiology Unit inthe Faculty of Medical andHuman Sciences and publishedthe first MFPDI paper in the PainJournal in October 2000.

The MFPDI is a Patient ReportedOutcome (PRO) measure, used byhealthcare clinicians as a majorindicator of quality in theassessment of patients'experience of treatment and care.

PRO measures provide a means ofgaining an insight into the waypatients perceive their health andthe impact that treatments oradjustments to lifestyle have ontheir quality of life.

Selected questions from theMFPDI have been used togenerate the Manchester OxfordFoot Questionnaire (MOxFQ),and both tools will now belicensed and supported by IsisOutcomes. Users of these PRO measures include thepharmaceutical industry andhealthcare providers as well asacademic researchers. IsisOutcomes continues to supportthe use of these PRO measuresby providing licences for non-commercial and academicuse free of charge.

Dr Garrow said: “Working withcolleagues from UMIP and IsisOutcomes has been a fantasticexperience. I am delighted thatthis agreement will continue toallow health care professionalsand researchers to have freeaccess to the MFPDI. In addition,the arrangement now opens theway to expand the use of theMFPDI in commerciallysponsored research projects.”

David Churchman, who heads upIsis Outcomes, commented: ”Weare pleased to add the MFPDI toour rapidly growing portfolio ofhigh quality condition-specificPRO measures. This is a greatexample of two of the UK’sleading universities collaboratingon technology transfer for thebenefit of patients and healthcare provision.”

PROGRESSPLATFORM™ - ONLINEPROGRESSION MONITORING SYSTEM

From L-R: Davina Whitnall, SimonMerrywest, Lauren Summers andGeorge Jeffries

www.isis-innovation.com/outcomes

Dr Mark Ashe from the Facultyof Life Sciences was nominatedas one of four finalists, and theonly University academic, for theInnovator of the Year categoryat the annual New EnergyAwards 2012 held at the ScienceMuseum in London on the 29thMarch. Now in their fifth year,the New Energy Awardsrecognise and reward only thebest individuals and companiescommitted to alternative sourcesof energy.

Winner of the category wasNujira, a company which delivers power efficient 3G/4Gwireless transmitters.

Dr Ashe is currently carrying outUMIP funded Proof-of-Principleresearch towards thedevelopment of geneticallymodified yeast which areoptimised for the production of butanol.

Increasing concerns over thefuture supply of fossil fuels,together with an increasedawareness of environmentalissues associated with the use ofthese non-renewable fuels hasled to growing interest in thedevelopment of biofuels.Biobutanol is similar to gasolineand so has a number ofadvantages over currently usedrenewable fuels such asbioethanol and biodiesel.

Dr Ashe comments: “I amdelighted to have beennominated as one of therunners-up in this prestigiousaward amongst some very stiffcompetition from establishedand highly respected companiesin the new energy sector. Butanol biofuels are an excitingalternative green fuel; throughmy research I am hoping toprovide a low cost solution toimproving the productionprocess such that on anindustrial scale, biobutanol can become a viable andeconomical alternative totraditional gasoline.”

UNIVERSITY OF MANCHESTER BIOFUELS RESEARCHERFINALIST AT NEW ENERGY AWARDS 2012

4

There has been a fantasticresponse to the call forExpressions of Interest (EoIs) tothe Co-Managed EnergyInnovation Fund which waslaunched to academics at theUniversity in September lastyear. 39 EoIs were received from11 different Schools, from whichthree innovations have beenchosen to receive funding andundertake one-year projects todemonstrate Proof-of-Principle.

The fund, launched by NationalGrid (NG), Scottish and SouthernEnergy Power Distribution(SSEPD), The University ofManchester Intellectual Property(UMIP) and The UMIP PremierFund (UPF), managed by MTIPartners, was created to identify and develop novelresearch and technologies forcommercialisation and utilisation by the distributionand transmission industry toimprove delivery of electricity to customers.

An Information Day, with anattendance of over 60, was heldby the partners at theUniversity’s Innovation Centre(UMIC). This provided academicswith information about theFund through a series of shortpresentations and round tablediscussions which explored anumber of key issues facing

electrical networks now and inthe future.

Of the three successfulinnovations, two originatedfrom Electrical and ElectronicEngineering (EPS) and one fromthe School of Environment and Development (Humanities).The successful innovators are as follows:

Professor Vladimir Terzija, EPSRCChair Professor in Power SystemEngineering from the School ofElectrical & ElectronicEngineering (EPS) - £160,000awarded by NG, UMIP andAlstom Grid to support thedevelopment of novel softwareto help prevent cascading blackouts and restore electricitysupplies as quickly as possibleafter a black out.

Dr Haiyu Li from the ElectricalEnergy and Power SystemsGroup at the School of Electricaland Electronic Engineering -£122,071 awarded by SSEPD, NGand UPF for the furtherdevelopment of novel optical ACcurrent sensor for use in anOptical Current Transformer -this will bring reliable costeffective Non-ConventionalInstrument Transformers to theglobal market where previouslythey have struggled to meetdistribution network operator’s

criteria. The technology will betrialled on the network duringthe Proof-of-Principle phase.

Dr Richard Kingston and Dr Jenni Viitanen from theSchool of Environment andDevelopment (SED), Faculty ofHumanities - £140,000 awardedby SSEPD and UMIP to create asoftware tool to engage energycustomers in the planning anddelivery of utility infrastructureas well as a mobile app (‘Tell Us’)to report faults in the energysupply and the exact location ofthe customer.

Martin Queen, SSEPD projectmanager, commented: “Theinterest in this competition fromthe University’s academiccommunity has been fantasticand demonstrates the depth and

breadth of the quality ofresearch and expertise across theinstitution. Via UMIP’s thoroughevaluation process, the panelhas uncovered three excitinginnovations which we would liketo evaluate further. With themassive challenges the electricalnetwork faces in the comingdecades, it is imperative thatnew and innovative solutionsare found and implemented. We are very much lookingforward to seeing how theseprojects evolve over the next 12 months.”

For further information, please contact:

Dr Frank Allison UMIP Venture ManagerFrank.Allison@umip.com0161 306 8831

CO-MANAGED ENERGY INNOVATION FUNDSPARKS INNOVATION RUSH…

Dr Mark Ashe

5

A Guide to UMIP

Case Studiesof Licensing

Case Studiesof Spin-outs

IP & Confidentiality

Spin-out Companies

Licensing

IP Workbook

Academic Materialsand Publishing

Download thefollowingguides andbooklets fromwww.umip.com

Hard copies available from:sarah.harris@umip.com

7 Years ofPositive Impact

5

Prof Ralf Paus, School of TranslationalMedicine, MHS Modulators for inhibiting hair follicle hair production > Licensing PoP awarded February 2012

Drs Jon Pittman and Patrick Gallois, FLSAlgae Biofuels> Spin-out PoP awarded March 2012

Prof. Henggui Zhang, School of Astronomyand Physics, EPSECG Analysis Software: diagnosis andstratification of clinical treatments for cardiac arrhythmias> PoP awarded April 2012

Professor Vladimir Terzija, School of Electrical& Electronic Engineering, EPSIntelligent Control Islanding & Power System Restoration> Licensing PoP awarded March 2012

Dr Haiyu Li, Electrical Energy and PowerSystems Group, School of Electrical andElectronic Engineering, EPSDual-Voas Based Optical Ac Current Sensor> Licensing PoP awarded January 2012

(Energy Fund)

Dr Xue Feng Yuan, School of ChemicalEngineering and Analytical Science, EPS Rheo Chip> Licensing PoP awarded December 2011

Prof Richard Kingston and Dr Jenni Viitanen,School of Environment and Development,HumanitiesTellUs – Engaging Energy Customers>Licensing PoP awarded January 2012

UMIP PROOF-OF-PRINCIPLE (PoP) AWARDS

We met with Dr Suresh Victor, a ConsultantNeonatologist from the DevelopmentalBiomedicine group within the School ofBiomedicine, to find out more about howUMIP Proof-of-Principle (PoP) funding hashelped him to add value to the commercialpotential of the neonatal EEG monitorsoftware that his team has been developing.

Nearly all babies born before 28 weeks’ ofpregnancy are ventilated for premature lungdisease. The purpose of ventilation is tomaintain normal blood oxygen and carbondioxide levels. Very low and very high bloodcarbon dioxide levels can result in injury to thebrain and lungs.

Current procedure involves taking spot checkblood samples to ensure that levels aremaintained within a normal range. On accountof the limitations on the amount of bloodsampling that can be done in small babies, dueto the potential for infection, the number ofspot checks is often restricted to once everyfour hours. This is suboptimal, as abnormalblood gas levels can remain undetected forprolonged periods of time.

The team has developed a software modulewhich can be integrated onto an existing EEGsystem which will provide continuousmonitoring of predicted blood gases to ensurethe optimal level of ventilation is beingachieved. This is a non-invasive way ofcontinuously monitoring blood carbon dioxidelevels and is therefore a highly desirable toolin the care of sick preterm newborn babies.

Dr Victor explains: “The technology useselectrical activity within the brain to measurethe predicted amount of CO2 in the blood. Withour software, we can estimate the effects ofblood CO2 on a vital end organ and change thebreathing support depending on the outputs.”

Initial funding came from MIMIT and as thetechnology was developing, Dr Victor met withUMIP Commercialisation Executive, Dr PushkarWadke, to discuss its patentability andcommercial potential. The technology wasawarded £60,000 of PoP Funding whichhelped fund a research assistant to develop thetechnology further and begin to use real dataon the technology.

UMIP have identified a major medicalequipment manufacturer in the Neonatalsetting who are interested in incorporatingthe software into their existing EEGequipment in order to bring the technology tomarket. A development project leading to alicensing deal is currently being discussed.

Dr Victor comments: “UMIP were extremelysupportive in the whole commercialisationprocess from patent protection, helping us toacquire funding and finding a companyinterested in taking the product to market. Iwould certainly encourage other academics toengage with UMIP.”

Please see our IP Awareness Resource atwww.manchester.ac.uk/ipresource for avaluable insight into the types of IP which canbe used to protect novel ideas/inventionsalong with a series of guides and bookletswhich you may find useful.

PROOF OF PRINCIPLE FUNDING CASE STUDY:

AN INTERVIEW WITH DR SURESH VICTOR

One of the significant added value aspects in technology transfer which attracts seed funders andlicensees is Proof-of-Principle funding.

To add value, UMIP manages, for the University, a ‘Proof-of-Principle’ account for projects withgood potential. We encourage you to find out more and make an application. Applications arereviewed throughout the year.

To find out more, please contact your UMIP Commercialisation Executive listed on the secondpage of this newsletter.

To illustrate the diversity of projects awarded since the last issue of our newsletter, please see below:

EPISTEM ANNOUNCES A THREE YEAR COLLABORATIONWITH GLAXOSMITHKLINE IN FIBROSIS RESEARCH

In March, Innovation Centretenant and University spin-out,Epistem, announced a three yearbiomarker collaboration withGlaxoSmithKline in the field offibrosis research. Thecollaboration will focus onidentifying key characteristics ofdiseased fibrotic tissue on which

Epistem will apply its proprietaryRNA-Amp™ technology tofacilitate building an in-depthunderstanding of the disease.

RNA-Amp™ is highly sensitiveamplification technology whichis able to provide geneexpression information fromsmall tissue samples and lownumbers of cells e.g. thoseobtained from the bulb of cellsat the base of a single hair

follicle, as well as laser capturedmicrodissected (LCM) samples.Epistem is now the preferredpartner of choice for a range of pharmaceuticalcompanies providing geneexpression biomarkerinformation to support drugdevelopment programmes.

In addition to its amplificationtechnology, Epistem brings itswell respected cell and

molecular biology expertise tothe collaboration. Epistem’sbroad platform allows proteinand gene expression biomarkersto be identified in importantdisease pathways at an earlystage of pre-clinical validationfor translation through to laterstage clinical validation andpatient stratification.

www.epistem.co.uk

NANOCO ACHIEVES US$1M PERFORMANCEMILESTONE FOR GREEN QUANTUM DOTS

Earlier this year, InnovationCentre tenant and Universityspin-out company, Nanocoannounced that it has achievedthe performance milestone forgreen quantum dots beingdeveloped in its supply andlicence agreement with a majorJapanese corporation, triggeringa US$1 million payment.

Nanoco is a world leader in thedevelopment and manufactureof cadmium-free quantum dotsand other nanomaterial.

The criteria for achieving themilestone included aperformance life of at least50,000 hours. Nanoco will nowbegin production of a 1kg batchof the green quantum dots.Once produced, and validatedby the customer, the 1kg batch

will attract a US$2 millionmilestone payment.

The performance milestone forthe green quantum dots followsthe successful production lastyear of a 1kg batch of redquantum dots for the same customer.

Michael Edelman, Nanoco'sChief Executive Officer, said:"We are delighted to havedemonstrated that theperformance of these greenquantum dots meets ourcustomer's specification as itmarks an important steptowards the customer's launchof a marketed product.

Last year, we successfullyproduced 1kg of red quantumdots for the same customer and

we will now begin productionof a 1kg batch of green dots.

The customer will then be able to combine the red andgreen dots with blue LEDs toproduce a highly efficientsource of white light formultiple potential applicationsincluding backlighting for LCD displays and LED-basedgeneral lighting.”

www.nanocotechnologies.com

GRAPHENE FUNDING CALLUMI3 and MTI’s UMIP PremierFund (UPF) are pleased toannounce the launch of a £1MGraphene and innovativematerials technologydevelopment funding call. This isfor Proof-of-Principle andfeasibility work, beyond theresearch grant stage. The UPFwill also be able to supply follow-on funding to thoseprojects which are successful atthe Proof-of-Principle stage andwhich continue to show goodpotential for commercialisation.

There is already a number ofacademics at the Universityworking on various existingUniversity proprietary graphenedevelopments, which have beenpart-funded by UPF.

Clive Rowland, UMI3 CEO, said:“with the positive news of theGovernment’s invitation for theUniversity to be the sole bidderfor the National GrapheneInstitute, we are keen tocomplement the amazing rangeof fundamental research andexperimental activity carried out

here by making additionalfunding available for thosecolleagues across the campuswho are interested intechnology transfer and keen totake the next steps beyond theirresearch results.”

Note: The details of the call for proposals will be issued inearly September with a shortclosing date. There will be aquick evaluation process with aview to successful proposalsstarting in Dec 2012/Jan 2013.

Please visit www.umip.comfor further details at the end of August.

Core Technology Facility46 Grafton Street

Manchester M13 9NTT: 0161 603 7751info@umip.comwww.umip.com

UMIP®The University of Manchester’s agent forIntellectual Property Commercialisation

UMIP is a division of The University of Manchester I3 Limited (UMI3)www.umi3.com

Printed on recycled paper

© The University of Manchester Intellectual Property 2012

Impression of a corrugatedgraphene sheet. Jannick Meyer